- Salix Pharmaceuticals (SLXP +5.2%) and Progenics Pharmaceuticals (PGNX) finally get a date for an Advisory Committee meeting regarding the companies' appeal of the complete response letter the FDA issued for Relistor in OIC for patients with chronic pain.
- The committee will convene on March 10-11 next year, after which time action on the appeal is expected within 30 days. (PR)
- Back in June, SLXP and PGNX noted that they were "optimistic that with the [help of the] FDA and guidance from the Advisory Committee, a path forward" could be found for the drug.
From other sites
at MarketWatch.com (Mar 16, 2015)
at CNBC.com (Mar 16, 2015)
at MarketWatch.com (Mar 11, 2015)
at Nasdaq.com (Feb 25, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs